Myriad Genetics Appoints Ben Wheeler as New CFO, Sees Potential Upside of 265.5%

Myriad Genetics has appointed Ben Wheeler as new CFO, effective August 16, 2025. Analysts predict a 25.51% potential upside for MYGN stock, while GuruFocus estimates a 265.5% upside based on GF Value metrics. Wheeler, a veteran at Myriad Genetics since 2011, has played a crucial role as the CFO of Operations since 2022.

Myriad Genetics, Inc. (NASDAQ: MYGN), a genetic testing and precision medicine company, has appointed Ben Wheeler as its new Chief Financial Officer (CFO), effective August 16, 2025. Wheeler, a veteran of Myriad Genetics since 2011, has been instrumental as the CFO of Operations since 2022 [1].

Analysts are optimistic about the potential impact of Wheeler's appointment. They predict a 25.51% potential upside for MYGN stock, while GuruFocus estimates a 265.5% upside based on GF Value metrics [2]. These predictions suggest a positive outlook for the company's financial performance and stock price.

Wheeler's extensive experience and deep understanding of Myriad Genetics' operations are likely to bring strategic financial insights to the executive team. His appointment comes at a critical juncture as the company navigates its growth trajectory and expands its precision medicine portfolio.

Investors should closely monitor Myriad Genetics' financial performance and market sentiment in the coming months. The appointment of a seasoned CFO like Wheeler can significantly influence the company's financial health and stock valuation.

References:
[1] https://www.marketbeat.com/stocks/NASDAQ/MYGN/
[2] https://www.marketbeat.com/stocks/NASDAQ/MYGN/